Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 68 articles:
HTML format



Single Articles


    October 2021
  1. MARTINEZ-MARTI A, Felip E, Mancuso FM, Caratu G, et al
    Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.
    Br J Cancer. 2021 Oct 1. pii: 10.1038/s41416-021-01558.
    PubMed     Abstract available


    September 2021
  2. LINDSAY CR, Shaw EC, Moore DA, Rassl D, et al
    Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
    Br J Cancer. 2021 Sep 6. pii: 10.1038/s41416-021-01407.
    PubMed     Abstract available


    August 2021
  3. ROSELL R, Cardona AF, Arrieta O, Aguilar A, et al
    Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.
    Br J Cancer. 2021 Aug 9. pii: 10.1038/s41416-021-01519.
    PubMed     Abstract available


    May 2021
  4. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01439.
    PubMed    


  5. CHENG Y, Wang Q, Li K, Shi J, et al
    Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01356.
    PubMed     Abstract available


  6. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 May 17. pii: 10.1038/s41416-021-01436.
    PubMed    


  7. ROUND T, L'Esperance V, Bayly J, Brain K, et al
    COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01361.
    PubMed     Abstract available


    April 2021
  8. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01278.
    PubMed     Abstract available


    March 2021
  9. JIANG Y, Martin J, Alkadhimi M, Shigemori K, et al
    Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01296.
    PubMed     Abstract available


  10. RAKAEE M, Kilvaer TK, Jamaly S, Berg T, et al
    Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01307.
    PubMed     Abstract available


  11. YANG H, Hall SRR, Sun B, Yao F, et al
    Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
    Br J Cancer. 2021;124:1177-1178.
    PubMed    


  12. WHITE MG, Eng OS
    Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
    Br J Cancer. 2021;124:1179-1180.
    PubMed    


  13. JIA L, Ge X, Du C, Chen L, et al
    EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-beta/SMAD signalling.
    Br J Cancer. 2021;124:1301-1311.
    PubMed     Abstract available


  14. SHIRASAWA M, Yoshida T, Horinouchi H, Kitano S, et al
    Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.
    Br J Cancer. 2021;124:925-932.
    PubMed     Abstract available


    February 2021
  15. ROSENTHAL R, Swanton C, McGranahan N
    Understanding the impact of immune-mediated selection on lung cancer evolution.
    Br J Cancer. 2021 Feb 24. pii: 10.1038/s41416-020-01232.
    PubMed     Abstract available


  16. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


  17. WHITE MG, Schulte JJ, Xue L, Berger Y, et al
    Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
    Br J Cancer. 2021;124:564-566.
    PubMed     Abstract available


    January 2021
  18. SURAWEERA A, Duff A, Adams MN, Jekimovs C, et al
    Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.
    Br J Cancer. 2021 Jan 26. pii: 10.1038/s41416-020-01242.
    PubMed    


  19. BRAGA A, Elias KM, Horowitz NS, Berkowitz RS, et al
    When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia.
    Br J Cancer. 2021 Jan 8. pii: 10.1038/s41416-020-01209.
    PubMed     Abstract available


  20. SUGANO T, Masuda M, Takeshita F, Motoi N, et al
    Pharmacological blockage of transforming growth factor-beta signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846.
    Br J Cancer. 2021;124:228-236.
    PubMed     Abstract available


  21. BAE K, Kim JH, Jung H, Kong SY, et al
    A fusion of CD63-BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis.
    Br J Cancer. 2021;124:290-298.
    PubMed     Abstract available


    December 2020
  22. BRANCHER S, Stoer NC, Weiderpass E, Damhuis RAM, et al
    Metformin use and lung cancer survival: a population-based study in Norway.
    Br J Cancer. 2020 Dec 2. pii: 10.1038/s41416-020-01186.
    PubMed     Abstract available


  23. LINDNER DJ, Wildey G, Parker Y, Dowlati A, et al
    CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01192.
    PubMed     Abstract available


  24. STOREY CL, Hanna GG, Greystoke A
    Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer.
    Br J Cancer. 2020;123.
    PubMed     Abstract available


  25. PATEL P, Alrifai D, McDonald F, Forster M, et al
    Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi(R), AstraZeneca UK Limited).
    Br J Cancer. 2020;123.
    PubMed     Abstract available


  26. CONIBEAR J
    Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.
    Br J Cancer. 2020;123.
    PubMed     Abstract available


  27. PAZ-ARES L
    Summary of 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
    Br J Cancer. 2020;123.
    PubMed    


  28. EVISON M
    The current treatment landscape in the UK for stage III NSCLC.
    Br J Cancer. 2020;123.
    PubMed     Abstract available


  29. PAZ-ARES L
    Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
    Br J Cancer. 2020;123.
    PubMed    


  30. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.
    PubMed    


  31. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.
    PubMed    


  32. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  33. KANG JH, Lee KH, Kim DW, Kim SW, et al
    A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
    Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01055.
    PubMed     Abstract available


    October 2020
  34. YANG L, Zhou F, Zhuang Y, Liu Y, et al
    Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Br J Cancer. 2020 Oct 30. pii: 10.1038/s41416-020-01135.
    PubMed     Abstract available


  35. HANSEN MS, Licaj I, Braaten T, Lund E, et al
    The fraction of lung cancer attributable to smoking in the Norwegian Women and Cancer (NOWAC) Study.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01131.
    PubMed     Abstract available


  36. SIDDIQUI MA, Gollavilli PN, Ramesh V, Parma B, et al
    Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01095.
    PubMed     Abstract available


  37. CREELAN BC, Yeh TC, Kim SW, Nogami N, et al
    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
    Br J Cancer. 2020 Oct 5. pii: 10.1038/s41416-020-01099.
    PubMed     Abstract available


  38. SONG X, Gong J, Zhang X, Feng X, et al
    Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
    Br J Cancer. 2020;123:1437-1444.
    PubMed     Abstract available


    September 2020
  39. KIM TW, Hong DW, Park JW, Hong SH, et al
    CB11, a novel purine-based PPAR ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells.
    Br J Cancer. 2020 Sep 22. pii: 10.1038/s41416-020-01088.
    PubMed     Abstract available


  40. AMBROISE G, Yu TT, Zhang B, Kacal M, et al
    Systematic analysis reveals a functional role for STAMBPL1 in the epithelial-mesenchymal transition process across multiple carcinomas.
    Br J Cancer. 2020;123:1164-1177.
    PubMed     Abstract available


  41. TRAN CHAU V, Liu W, Gerbe de Thore M, Meziani L, et al
    Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.
    Br J Cancer. 2020;123:762-771.
    PubMed     Abstract available


    August 2020
  42. MACBETH F, Fallowfield L
    The myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:499-500.
    PubMed     Abstract available


  43. LI PETRI G, El Hassouni B, Sciarrillo R, Funel N, et al
    Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
    Br J Cancer. 2020;123:644-656.
    PubMed     Abstract available


  44. KOSMIDIS C, Sardeli C, Zarogoulidis P, Hohenforst-Schmidt W, et al
    Producing the appropriate model and drug for intratumoural ablation.
    Br J Cancer. 2020;123:335-336.
    PubMed     Abstract available


  45. NIEMEIJER AN, Sahba S, Smit EF, Lissenberg-Witte BI, et al
    Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
    Br J Cancer. 2020;123:392-402.
    PubMed     Abstract available


    July 2020
  46. GOMES F, Wong M, Battisti NML, Kordbacheh T, et al
    Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
    Br J Cancer. 2020 Jul 22. pii: 10.1038/s41416-020-0986.
    PubMed     Abstract available


  47. LUANPITPONG S, Rodboon N, Samart P, Vinayanuwattikun C, et al
    A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma.
    Br J Cancer. 2020 Jul 20. pii: 10.1038/s41416-020-0991.
    PubMed     Abstract available


  48. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed     Abstract available


    June 2020
  49. CICCOLINI J, Benzekry S, Barlesi F
    Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.
    Br J Cancer. 2020 Jun 16. pii: 10.1038/s41416-020-0918.
    PubMed     Abstract available


  50. ALAM SK, Wang L, Ren Y, Hernandez CE, et al
    ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
    Br J Cancer. 2020 Jun 5. pii: 10.1038/s41416-020-0923.
    PubMed     Abstract available


    May 2020
  51. ROSSI SM, Ryan BK, Kelly HM
    Evaluation of the activity of a chemo-ablative, thermoresponsive hydrogel in a murine xenograft model of lung cancer.
    Br J Cancer. 2020 May 27. pii: 10.1038/s41416-020-0904.
    PubMed     Abstract available


  52. HSIN IL, Chiu LY, Ou CC, Wu WJ, et al
    CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum.
    Br J Cancer. 2020 May 25. pii: 10.1038/s41416-020-0885.
    PubMed     Abstract available


  53. SURAWEERA A, Duff A, Adams MN, Jekimovs C, et al
    Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0899.
    PubMed     Abstract available


  54. WELCH CA, Sweeting MJ, Lambert PC, Rutherford MJ, et al
    Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a VICORI study.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0869.
    PubMed     Abstract available


  55. ZULATO E, Attili I, Pavan A, Nardo G, et al
    Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
    Br J Cancer. 2020 May 7. pii: 10.1038/s41416-020-0833.
    PubMed     Abstract available


    April 2020
  56. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2020 Apr 29. pii: 10.1038/s41416-020-0845.
    PubMed     Abstract available


  57. SAITO R, Miki Y, Abe T, Miyauchi E, et al
    11beta hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0837.
    PubMed     Abstract available


  58. JETTE NR, Radhamani S, Arthur G, Ye R, et al
    Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Br J Cancer. 2020 Apr 17. pii: 10.1038/s41416-020-0841.
    PubMed     Abstract available


  59. DAI W, Wang G, Chwa J, Oh ME, et al
    Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer.
    Br J Cancer. 2020;122:1288-1297.
    PubMed     Abstract available


  60. VAN GEEL RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al
    Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    Br J Cancer. 2020;122:1166-1174.
    PubMed     Abstract available


    March 2020
  61. SAITO Y, Takahashi T, Obata Y, Nishida T, et al
    TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours.
    Br J Cancer. 2020;122:658-667.
    PubMed     Abstract available


  62. ZHANG Q, Ganapathy S, Avraham H, Nishioka T, et al
    Nicotine exposure potentiates lung tumorigenesis by perturbing cellular surveillance.
    Br J Cancer. 2020;122:904-911.
    PubMed     Abstract available


    February 2020
  63. WATTENBERG MM, Asch D, Yu S, O'Dwyer PJ, et al
    Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    Br J Cancer. 2020;122:333-339.
    PubMed     Abstract available


    January 2020
  64. URSO L, Cavallari I, Sharova E, Ciccarese F, et al
    Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
    Br J Cancer. 2020;122:52-61.
    PubMed     Abstract available


    December 2019
  65. HOU P, Shi P, Jiang T, Yin H, et al
    DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0695.
    PubMed     Abstract available


    September 2019
  66. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available


    August 2019
  67. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
    Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
    PubMed     Abstract available


    July 2019
  68. ELEZ E, Pericay C, Valladares-Ayerbes M, Bando I, et al
    A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Br J Cancer. 2019 Jul 31. pii: 10.1038/s41416-019-0537.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: